Novartis Reveals Two COPD Drugs’ Positive Phase III Results and NDA Submission
COPD, News
Novartis recently announced robust findings from a pivotal Phase III clinical study for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide), meant to support these pipeline medications’ New Drug Applications with the ... Read more